Amy Calistri
Stock of the Month
Stephen Leeb
Income Performance Report
Roger Conrad
The Utility Forecaster
Paul McWilliams
Next Inning

Global experts see 'emerging' gains in global telecoms


Bookmark and Share

 For their favorite stocks for 2008, three leading global investing experts turned to telecom companies that are focused on emerging markets.

Here, Nick Vardy looks at  Millicom International Cellular (NASDAQ: MICC); Yiannis Mostrous recommends Mobile TeleSystems (NYSE: MBT); and John Christy chooses Philippines Long Distance Telecom (NYSE: PHI). Here are their reviews.

Yiannis Mostrous, editor of The Silk Road Investor, explains, "Mobile TeleSystems is the largest cellular operator in Eastern Europe, with 50 million subscribers. It has licenses in 87 Russian regions, Ukraine, Belarus, Uzbekistan and Turkmenistan, covering a population of more than 233 million people.

"Russia accounts for almost 80% of consolidated revenue, while Ukraine is the second largest contributor. This is a company that offers good exposure to Russia’s domestic demand growth. 

"Russia is currently in a sweet spot: It’s a net oil exporter, has good GDP growth, isn’t dependent on foreign capital flows, is relatively stable politically, boasts reasonable market valuations and, above all, enjoys solid exposure to the biggest growth story of our time, Asia.

"Mobile Telesystems will continue to experience strong growth given the regional economic strength.  Its valuations are still reasonable and it actually trades at a discount to a lot of its peers in the emerging market universe. This should make it a stock to own going into what is shaping to be an uncertain New Year.

Advertisement
Banner

"The company’s investments in its various markets have started producing positive results and it is also continues to consolidates operations while taking advantage of market growth."

Nick Vardy, editor of The Global Stock Investor,  says, "My favorite conservative investment idea for 2008 is Millicom. The explosion in cell phone usage is one of my favorite 'top down' themes in global investing.

"No technology has spread wider and more quickly than cell phones. While it took TVn 30 years to penetrate households across the globe, cell phones managed to achieve this in less than a single decade.

"Millicom is  the 'Indiana Jones' of the cell phone industry. It is one of a handful of global players that are profiting from expansion in cell phone markets where others fear to tread.

"Millicom's strategy has been unique and daring. It has cobbled together a patchwork empire that consists of 16 countries in Central America, South America, Africa, South and Southeast Asia. Today Millicom has 20 million subscribers.

"By picking unsexy markets -- ones that are under the radar of the major wireless firms -- Millicom has been profiting handsomely as demand for cell phone services has exploded. Just how successful has this strategy been? Millicom's split adjusted stock price has increased close to 120-fold since July of 2002.

"Today, it boasts market capitalization of more than $12.5 billion. Not bad, for the runt of the cell phone litter. Although most of Millicom's sales growth has come from traditional Latin American properties, more than half of Millicom's customers today are in Africa and Asia.

"Given the relatively low cell penetration rates, Africa is the fastest growing region of the world in terms of cell phone use.  Cell phone penetration is only 14% compared with 20% in the Middle East, 25% in Asia and more than 80% in Western Europe.

"Another vote of confidence? The chief executive officer of Millicom recently exercised 700,000 shares of stock options. Whether the company grows on its own or is taken over by one of the major cell phone companies, I expect Millicom's stock to continue to soar in 2008."

John Christy, editor of The Forbes International Investment Report, explains, "If China is Asia's ultimate growth story, the Philippines qualifies as the region's biggest turnaround story.

"Long plagued by political instability and disastrous economic policies, the Philippines is finally getting its act together under President Gloria Macapagal Arroyo. Economists expect GDP growth of nearly 7% this year and foreign investment capital is pouring into the country.

"My favorite stock for 2008 is Philippines Long Distance Telecom, which is an easy way for U.S. investors to get a piece of the action. It is the leading provider of wireless telecom services in the Philippines with nearly a 60% market share.

"But wireless penetration rates in the Philippines are among the lowest in Asia, suggesting considerable room for future growth before the market becomes saturated. And broadband services in the Philippines are still in their infancy.

"PHI is currently trading at 13 times estimated 2008 earnings and roughly 7 times earnings before interest taxes depreciation and amortization (EBITDA). That makes PHI one of the cheapest names in the emerging markets telecom universe. Investors in PHI also enjoy a dividend yield of more than 5% as an added bonus."


Banner
News Flash

Linkedin: Professional profits
by Leo Fasciocco, editor Ticker Tape Digest

Online professional network operator Linkedin (LNKD) recently moved above its technical breakout point of $108.53. We now target a move to $138.


Read more...

 

Tap in to water stocks
by Doug Fabian, editor Making Money Alert

As we prepare for the summer heat, water presents a significant investment opportunity -- especially as states such as California and Texas face droughts. The PowerShares Water Resource ETF (PHO) presents one way to invest in water's untapped potential.


Read more...


   

Pax World: High yield exception
by Amy Calistri, editor The Daily Paycheck

I generally prefer closed-end or exchange-traded funds because the fees tend to be lower. But I made a special case for Pax World High Yield Bond (PAXHX); this high-yield bond fund is my only open-ended mutual fund holding.


Read more...

 

Amgen: Biotech DRIP
by Chuck Carlson, editor DRIP Investor

Amgen (AMGN) is one of the oldest and largest players in the biotechnology area. It pioneered the development of products based on advances in recombinant DNA and molecular biology, launching the biotechnology industry’s first blockbuster medicines.


Read more...

 

Fidelity fund expert looks to Japan
by Jim Lowell, editor Fidelity Investor

In my May Marketwatch investment strategy column I noted, “Set against the backdrop of having already been thrown out with the Eurozone’s bathwater, I like Japan’s marketplace overall and, more specifically, their small cap marketplace which caters to domestic counter traffic.”


Read more...

 

MOO: Market Vectors Agribusiness
by Doug Fabian, editor Making Money Alert

Everyone needs food to survive, so wouldn't it be great to make money from it? We can. The global agriculture business provides a fairly stable investment with growth potential. In particular, I am looking at Market Vectors Agribusiness ETF (MOO).


Read more...

 

Celgene: Selloff creates opportunity
by J. Royden Ward, editor Cabot Benjamin Graham Value Letter

Celgene (CELG) develops and assists in the marketing of drugs to treat cancer and infl ammatory diseases. It acquired several companies recently, which will expand its product line and add promising products in various stages of development.


Read more...

 

Senior housing reits for income
by Brian Hicks, editor Wealth Advisory

Omega Healthcare Investors (OHI) and Medical Properties Trust (MPW) caters to the senior housing/assisted living facilities. Given the growing senior population, it makes sense to be somewhat over-exposed to companies that target this market.


Read more...

 

Buffett: Still banking on banks
by Ron Rowland, editor All Star Investor

Wise investors zero in on conflicting data points. Warren Buffett, the wisest investor of all, provided plenty to consider at the Berkshire Hathaway annual meeting. 


Read more...

 

Questcor: 'Exponential demand'
by Dennis Slothower, editor Stealth Stocks

Questcor Pharmaceuticals (QCOR), our latest featured stock of the month, is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.


Read more...

 



Banner



Close
Select Offer: Schwab Options Market Commentary